@psoriasisclub.orgAt Psoriasis Club you'll find a friendly bunch of people sharing information & support. We know what it's like living with psoriasis & have built up a huge amount of information on the topic.
We have no sponsors or advertising, we are just people living with #Psoriasis
@psoriasisclub.orgCould targeting macrophage cannabinoid 1 receptor (CB1R) be a new therapeutic strategy for psoriasis ?
@kernelmedstarry.bsky.socialADV 2026 Vienna has come to a close 🎬
A heartfelt thank you to every dermatologist, clinic owner and global partner who stopped by Kernel’s booth for conversations & product demos!
#EADV2026 #Dermatology #Phototherapy #Vitiligo #Psoriasis #Alopecia #KernelMedical #MedicalDevice
@psor.orgPsoriatic Disease UK is run entirely by volunteers — people who live with or care deeply about these conditions, giving their time to support this community.
If what we do has ever helped you, thank you for being here.
@drcadesky.bsky.socialExercise is an important part of health
and can improve symptoms of #psoriasis
@amm-journal.orgThe discovery of avicularin as a novel IL-17RA inhibitor provides a strong foundation for future #psoriasis therapies by demonstrating direct target engagement and significant in vivo efficacy. #medsky #Pharmacology
#AMM #OpenAccess: doi.org/10.15212/AMM...
@psor.orgNew on the PSOR blog: "Help Us Show What Psoriatic Disease Really Looks Like."
The story behind PSOR Perspective, and why real images from real people change things.
Read it: https://f.mtr.cool/du21s66yvt
#PSORPerspective #PsoriaticDisease #Psoriasis #ChronicIllness
@psoriasisclub.orgNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity.
@psoriasisclub.orgThis study presents a dual action microneedle therapy for psoriasis that alleviates psoriasis by modulating keratinocyte ferroptosis and scavenging cfDNA to restore inflammatory homeostasis.
@replaye.bsky.socialGLP-1 combination therapy may unlock new benefits for psoriasis patients
replaye.com/glp-1-combin...
@psoriasisclub.orgThis study evaluated whether IL-17A and IL-23p19 inhibitors improve psychiatric symptoms in psoriasis patients, and whether these improvements are associated with reductions in inflammatory markers, independently of skin response.
@psoriasisclub.orgIn this retrospective real-world cohort of patients with moderate-to-severe plaque psoriasis treated with Cosentyx (secukinumab), higher baseline low-density lipoprotein cholesterol (LDL) showed a directionally inverse association.
@pharmaphorum.bsky.socialA study has shown that the efficacy of #EliLilly's #psoriasis therapy #Taltz is improved when it is given in #combination with the company's blockbuster #weightloss therapy #Zepbound.
@psoriasisclub.orgPhoto-controlled prodrug strategy can provide a platform for designing smart drug delivery systems to ameliorate psoriasis-like skin inflammation.
@toppnews.bsky.social#cancer #Heart failure #Psoriasis
🌐 www.newsmart.ch
@newsen.bsky.socialJohnson & Johnson's ICOTYDE® Shows Promising Two-Year Results in Psoriasis Treatment #USA #Johnson_&_Johnson #Spring_House #Psoriasis #ICOTYDE
@dailynorthern.comGovernment plans to end funding for psoriasis treatment trips #Croatia #healthcare #psoriasis
@dailynorthern.comGovernment removes funding for patients’ treatment abroad #healthcare #psoriasis #rheumatism
@psoriasisclub.orgIn this retrospective cohort of 228 Chinese patients with chronic plaque psoriasis, 52 weeks of Tremfya (guselkumab) treatment was associated with a modest but statistically significant reduction in serum uric acid.
@yuuiko7.bsky.social$JNJ two-year data from the ICONIC-TOTAL trial shows icotinib delivering strong clearance at psoriasis's hardest-to-treat sites.
- 60% complete scalp clearance at Week 112
- 89% complete genital clearance at Week 112
- Results hold through two full years of treatment